Brief: Zevra Therapeutics Provides Update On Regulatory Submission For Arimoclomol
24/07/2026 12:34
BRIEF-Zevra Therapeutics Provides Update On Regulatory Submission For Arimoclomol July 24 (Reuters) - Zevra Therapeutics Inc ZVRA.O:
ZEVRA THERAPEUTICS PROVIDES UPDATE ON REGULATORY SUBMISSION FOR ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C (NPC) IN THE EUROPEAN UNION
ZEVRA THERAPEUTICS - CHMP ADOPTS NEGATIVE OPINION ON ARIMOCLOMOL MAA FOR NIEMANN-PICK DISEASE TYPE C
ZEVRA THERAPEUTICS - TO REQUEST RE-EXAMINATION OF CHMP OPINION ON ARIMOCLOMOL
Source text: ID:nGNX9hcgpK
Further company coverage: ZVRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor